FDA grants Illumina 510(k) clearance for VeraCode Genotyping Test for Factor V and Factor II

Illumina, Inc. (NASDAQ:ILMN) today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) market clearance for the VeraCode® Genotyping Test for Factor V (Leiden) and Factor II (Prothrombin).

The VeraCode Genotyping Test is comprised of the company's VeraCode digital microbead technology and proprietary assay chemistry. The BeadXpress® System, which received a separate 510(k) market clearance, is FDA-cleared for in vitro diagnostic use only with the VeraCode Genotyping Test for Factor V and Factor II.

Source Illumina

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Illumina, Inc.. (2018, July 27). FDA grants Illumina 510(k) clearance for VeraCode Genotyping Test for Factor V and Factor II. News-Medical. Retrieved on July 14, 2024 from https://www.news-medical.net/news/20100519/FDA-grants-Illumina-510(k)-clearance-for-VeraCode-Genotyping-Test-for-Factor-V-and-Factor-II.aspx.

  • MLA

    Illumina, Inc.. "FDA grants Illumina 510(k) clearance for VeraCode Genotyping Test for Factor V and Factor II". News-Medical. 14 July 2024. <https://www.news-medical.net/news/20100519/FDA-grants-Illumina-510(k)-clearance-for-VeraCode-Genotyping-Test-for-Factor-V-and-Factor-II.aspx>.

  • Chicago

    Illumina, Inc.. "FDA grants Illumina 510(k) clearance for VeraCode Genotyping Test for Factor V and Factor II". News-Medical. https://www.news-medical.net/news/20100519/FDA-grants-Illumina-510(k)-clearance-for-VeraCode-Genotyping-Test-for-Factor-V-and-Factor-II.aspx. (accessed July 14, 2024).

  • Harvard

    Illumina, Inc.. 2018. FDA grants Illumina 510(k) clearance for VeraCode Genotyping Test for Factor V and Factor II. News-Medical, viewed 14 July 2024, https://www.news-medical.net/news/20100519/FDA-grants-Illumina-510(k)-clearance-for-VeraCode-Genotyping-Test-for-Factor-V-and-Factor-II.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
MLL, IBM and Illumina collaborate to build new cognitive technology prototype for improving leukemia treatment